NASDAQ:INCYIncyte Stock Price, Forecast & News

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, INCY shares have increased by 48.1% and is now trading at $106.47. View which stocks have been most impacted by Coronavirus.

23 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Incyte.

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Incyte.

Incyte Co. (NASDAQ:INCY) posted its quarterly earnings data on Tuesday, May, 5th. The biopharmaceutical company reported ($2.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.31 by $3.17. The biopharmaceutical company had revenue of $568.51 million for the quarter, compared to analyst estimates of $553.24 million. Incyte had a negative return on equity of 12.81% and a negative net margin of 16.87%. The company's revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 earnings per share. View Incyte's earnings history.

23 Wall Street analysts have issued 12-month price objectives for Incyte's stock. Their forecasts range from $79.00 to $124.00. On average, they expect Incyte's share price to reach $100.65 in the next year. This suggests that the stock has a possible downside of 5.5%. View analysts' price targets for Incyte.

Press coverage about INCY stock has trended negative this week, according to InfoTrie. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Incyte earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the near future. View the latest news about Incyte.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Micron Technology (MU), Array Biopharma (ARRY) and Celgene (CELG).

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $106.47.

Incyte has a market capitalization of $23.14 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.

The official website for Incyte is www.incyte.com.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]